Curevac Archives

ablynx antibodies rsv infection nanobody llama

News and Trends 18 Dec 2015

64 Million RSV Infections Per Year: Perhaps Alpaca Nanobodies Will Save Infant Lives

Ablynx, the Alpaca Nanobody Biotech from Belgium, has completed target enrollment of the first-in-infant Phase I/IIa study with its anti-Respiratory Syncytial virus, which is linked to 3,000-8,500 infant deaths each year. ALX-0171 is a wholly-owned Nanobody drug candidate administered through inhalation (nebulisation), for the treatment of respiratory syncytial virus (RSV) infection in infants. The candidate […]

December 18, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 12 Nov 2015

Interview: CureVac, the ‘RNA’ People’s Pioneering Strategy to get mRNA Therapies onto the Market

I am still at the mRNA Convention in Berlin…and was invited for a second interview – this time with the ‘RNA People’, battling to be the first to get an mRNA Drug onto the Worldwide Market. I had a chat with Franz-Werner Haas, the Chief Corporate Office of CureVac. We talked a lot about this […]

November 12, 2015 - 1 minutemin - By Philip Hemme

News and Trends 7 Nov 2015

What Happened this Week? BIO-Europe 2015, mRNA deal, Cellectis CAR-T

Monday: The French Scientist Who Also ‘Discovered’ CRISPR is Finally Recognized with a Prize too Tuesday: €100 Million Investment Round Prepares CureVac For Vaccine Expansion Wednesday: €1.37Bn Deal for Sanofi with Germany’s Fastest Growing mRNA Cancer Biotech Thursday: Damn, that was BIO-Europe 2015 in Munich! Friday: Cellectis’ Miraculous Saving of a Baby Girl. What’s the impact on […]

November 7, 2015 - 1 minutemin - By Philip Hemme

News and Trends 14 Sep 2015

64 million infected: A brief overview of ReViral and its RSV vaccine competition

Respiratory Syncytial Virus (RSV) affects millions annually, therefore attracting many large biotechs to research a vaccine. ReViral (London, UK) has secured €18.5M series A investment into its pre-clinical pipeline. VC investors Edmond de Rothschild, OrbiMed and Brace Pharma Capital back this award winning antiviral program, despite an array of competitors. ReViral have got the go […]

September 14, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 13 Sep 2015

What happened this week? An award for Kymab, disappointment for Crowdfunding and some Wasps to save us!

Monday: A report said that the total value of crowdfunded Biotech projects from within the EU since 2010 is €23M. Tuesday: Researchers from University of Leeds unraveled the mechanism of cancer-targeting effects of Wasp venom. Wednesday: Kymab has been listed in the Sunday Times Tech Track ‘One’s to Watch’ 2015 just this month! Thursday: CureVac just announced the opening of its subsidiary […]

September 13, 2015 - 1 minutemin - By Joachim Eeckhout

News and Trends 10 Sep 2015

CureVac, the mRNA Therapy Leader, is invading Moderna’s Homeland!

One more hit to Moderna Therapeutics struck by its German competitor CureVac! The Tübingen-based company just announced the opening of its subsidiary in Boston – hometown of Moderna – and a research collaboration with the U.S. non-profit International AIDS Vaccine Initiative (IAVI) to develop a mRNA-based HIV treatment. CureVac, today announced the official launch of its U.S. operations in […]

September 10, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 7 Aug 2015

Bill & Melinda Gates’ Faith in CureVac is Leading to a New Program

CureVac, a pioneer in the field of mRNA-based technology, today announced that the company has initiated its third target product development program in collaboration with the Bill & Melinda Gates Foundation. The program will leverage CureVac’s RNActive technology platform in the development of a prophylactic vaccine to protect against respiratory syncytial virus (RSV), adding to […]

August 7, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 8 Jul 2015

CureVac’s mRNA Therapy is Working Against Prostate Cancer

mRNA based immunotherapies are no pipe dream anymore. Germany’s CureVac just presented encouraging results of its Phase IIa clinical study. The firm’s lead mRNA candidate CV9103 is well tolerated and immunogenic in patients with prostate cancer. Based on the favorable data, CureVac initiated a Phase IIb study with a follower prostate cancer vaccine. Just recently, […]

July 8, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 1 Jul 2015

mRNA Therapies: CureVac Outperformed the Money Magnet Moderna

Everybody has already heard about Boston-based Moderna Therapeutics, the most highly valued venture-backed private Biotech, but CureVac, its German competitor, remains much more understated. This could rapidly change as CureVac just demonstrated that its technology beats Moderna’s. mRNA technologies could theoretically disrupt the whole drug industry. Imagine that you can directly inject mRNA into patients to make them produce their own therapeutic proteins. Unfortunately, […]

July 1, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 4 Jun 2015

Lesson to Learn from the Best Biotech Entrepreneurs: be a Pioneer!

Last week, Biotech Entrepreneurs gathered in Berlin for the Charité Entrepreneurship Summit 2015. As a spectator, I’ll bring you the most important lessons to take on board from successful entrepreneurs. The First speaker was James Sabry, Senior VP at Genentech, which I already interviewed on the strategy of Genentech/Roche. The Californian entrepreneur, who founded the NASDAQ-listed company Cytokinetics before joining Genentech, gave […]

June 4, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 22 Sep 2014

Is a new revolution in lung cancer drug treatment coming ?

A new revolutionary treatment could help cure lung cancer. It is based on mRNA instead of antibodies and chemotherapy. Instead of delivering the protein or the drug, only a message is delivering and the body will produce the therapeutics. Curevac, the historic and one of the leading Biotech company in this field announced a 465 million […]

September 22, 2014 - 3 minutesmins - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us